Immunotherapy最新文献

{"title":"ICAM2 is related to good prognosis in dendritic cell immunotherapy for cancer.","authors":"Saulo Fm da Silva, Eddie Fc Murta, Márcia A Michelin","doi":"10.2217/imt-2021-0097","DOIUrl":"10.2217/imt-2021-0097","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the behavior of adhesion molecules ICAM-1 and ICAM-2 in dendritic cell (DC) immunotherapy. <b>Materials & methods:</b> 88 female Balb/c mice were divided into experimental groups. Tumors and lymph nodes were evaluated 7 and 14 days after immunotherapy. <b>Results:</b> Higher mean fluorescence intensity of ICAM-1 in the lymph nodes and tumors in the tumor group at 14 days was observed. Higher mean fluorescence intensity of ICAM-2 in the tumor DC vaccine group was observed after 14 days. A positive correlation was observed in the lymph nodes with ICAM-1 against tumoral volume in the tumor group. A negative correlation was found between ICAM-2 and tumoral volume in the lymph nodes of the tumor group. <b>Conclusion:</b> An increase in ICAM-2 in tumor DC vaccine and a decrease in ICAM-1 suggests the DC vaccine positively influences the immune system and that ICAM-2 could be a marker of good prognosis.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"173-185"},"PeriodicalIF":2.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular toxicities in chimeric antigen receptor T-cell therapy: a real-world study leveraging FAERS database.","authors":"Na Zhao, Fangyuan Hu, Yinghong Zhai, Xia Ye, Yiming Ruan, Zhen Liu, Zhiyan Wang, Wei Shen, Lei Yuan","doi":"10.2217/imt-2023-0220","DOIUrl":"10.2217/imt-2023-0220","url":null,"abstract":"<p><p><b>Aim:</b> The purpose of this study was to comprehensively explore the ocular toxicity associated with chimeric antigen receptor (CAR) T-cell therapy. <b>Materials & methods:</b> Data were assembled from the US FDA's Adverse Event Reporting System (FAERS) database from 2017 to 2023. Information component and reporting odds ratio methods were used for signal detection in total/categorized CAR T-cell therapy. <b>Results:</b> A total of 17 positive signals (preferred term) were detected, yet none of them were documented in the product information. Some adverse events were with death outcomes and overlapped a lot with cytokine-release syndrome. <b>Conclusion:</b> The ocular adverse events associated with CAR-T cell therapy are noteworthy, and it is imperative to maintain increased alertness and institute early intervention strategies.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"161-172"},"PeriodicalIF":2.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncolytic viruses in lung cancer treatment: a review article.","authors":"Hanie Sakhi, Mohadeseh Arabi, Amir Ghaemi, Abolfazl Movafagh, Mojgan Sheikhpour","doi":"10.2217/imt-2023-0124","DOIUrl":"10.2217/imt-2023-0124","url":null,"abstract":"<p><p>Lung cancer has a high morbidity rate worldwide due to its resistance to therapy. So new treatment options are needed to improve the outcomes of lung cancer treatment. This study aimed to evaluate the effectiveness of oncolytic viruses (OVs) as a new type of cancer treatment. In this study, 158 articles from PubMed and Scopus from 1994 to 2022 were reviewed on the effectiveness of OVs in the treatment of lung cancer. The oncolytic properties of eight categories of OVs and their interactions with treatment options were investigated. OVs can be applied as a promising immunotherapy option, as they are reproduced selectively in different types of cancer cells, cause tumor cell lysis and trigger efficient immune responses.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"75-97"},"PeriodicalIF":2.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-tumor immunity and vitiligo: from immune-related adverse reactions to protection from cancer.","authors":"Roberto Mazzetto, Alvise Sernicola, Paola Miceli, Jacopo Tartaglia, Christian Ciolfi, Mauro Alaibac","doi":"10.1080/1750743X.2024.2377954","DOIUrl":"10.1080/1750743X.2024.2377954","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"841-843"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141763974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis.","authors":"Bora Nam, Tae-Hwan Kim","doi":"10.2217/imt-2023-0015","DOIUrl":"10.2217/imt-2023-0015","url":null,"abstract":"<p><p>Nonradiographic axial spondyloarthritis (nr-axSpA) is a subtype of SpA with undeveloped definite radiographic sacroiliitis. Tumor necrosis factor inhibitors have demonstrated effectiveness in nr-axSpA patients who do not respond to first-line therapy. More recently, accumulated data from genetic, experimental, and clinical studies revealed that IL-17 is a key player in the pathogenesis of SpA, leading to development of new biologics directly inhibiting IL-17. Among them, ixekizumab is a high-affinity monoclonal antibody that selectively targets IL-17A and has exhibited significant efficacy and acceptable safety profiles in the treatment of nr-axSpA. The aim of this paper is to narratively review the recent insights of IL-17 in the pathogenesis of axSpA and discuss the effectiveness and safety of ixekizumab in treatment of nr-axSpA.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"569-580"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epicutaneous immunotherapy with Viaskin^™ Peanut in toddlers: a plain language summary.","authors":"David R Stukus, Ruchi Gupta, Douglas Mack, Lianne Mandelbaum, Dareen Siri, Vivian Hernandez-Trujillo, Hugh A Sampson","doi":"10.2217/imt-2023-0201","DOIUrl":"10.2217/imt-2023-0201","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a summary of an article published in <i>The New England Journal of Medicine</i> about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy in children aged 1 through 3 years. The patch is a form of epicutaneous immunotherapy (EPIT), which is a new approach to allergen immunotherapy that delivers a small amount of peanut protein to the immune system through the skin. Viaskin Peanut is an investigational therapy, meaning it has not yet been approved by the United States Food and Drug Administration (FDA), that has been studied before in young children aged 4 through 11 years. In those studies, the children who received the patch were desensitized and were less likely to experience anaphylaxis when they ate peanut at the end of the study. The EPITOPE study included children aged 1 through 3 years with peanut allergy and looked at how well the peanut patch worked and how safe it was compared to a patch with no medicine (placebo, no medicine) after 12 months.</p><p><strong>What were the key takeaways?: </strong>The study showed that the peanut patch was better in desensitizing children to peanuts than the placebo patch. Most of the children in the study who received the peanut patch for 12 months (the treatment group) were able to eat and tolerate more peanut at the end of the study than those who received only the placebo patch (the control group). This demonstrates that the children in the treatment group were less likely to have an allergic reaction if they ate peanut by accident at the end of the study. The children in the treatment group also had less severe symptoms when they were given peanut during the oral <b>food challenges</b> at the end of the study. Most children in both groups experienced side effects. Mild to moderate local skin reactions where the patch was applied were most common. These side effects happened less often and were less serious over the 12-month treatment period.</p><p><strong>What were the main conclusions reported by the researchers?: </strong>Overall, these results show the peanut patch may be a possible treatment option to help desensitize young children with peanut allergy to peanut.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"16 1","pages":"5-13"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of nemolizumab in the treatment of atopic dermatitis for the adult population.","authors":"Stuti Prajapati, Joseph P Flemming, Danyaal Khan, Haowei Han, Brian How, Suzanne Sirota Rozenberg, Steven R Feldman","doi":"10.1080/1750743X.2024.2383554","DOIUrl":"10.1080/1750743X.2024.2383554","url":null,"abstract":"<p><p>Atopic dermatitis (AD) often requires long-term treatment that may be associated with adverse effects. This review aims to characterize nemolizumab as a treatment for AD in adults. A literature search was performed to assess nemolizumab's role in moderate-to-severe AD in adults. Currently, clinical trials are being conducted to evaluate the clinical efficacy, safety profile and optimal dosing of nemolizumab for adults with moderate-to-severe AD. The most common adverse effects include nasopharyngitis, AD exacerbation and increased blood creatinine phosphokinase. Recent data from clinical trials suggest nemolizumab may be an acceptable treatment in adults with moderate-to-severe AD.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"925-935"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha/beta-defensins influence on the humoral immunity and complications in cancer of the oral cavity and oropharynx.","authors":"Halyna Hirna, Dmitry Maltsev","doi":"10.1080/1750743X.2024.2376517","DOIUrl":"10.1080/1750743X.2024.2376517","url":null,"abstract":"<p><p><b>Aim:</b> Patients with cancer of the oral cavity and oropharynx (COCO) often exhibit signs of immunosuppression, affecting their prognosis. Understanding the dynamics of humoral immunity in these patients during chemoradiation therapy is crucial for developing effective treatments.<b>Materials & methods:</b> This prospective study included 105 COCO patients undergoing different treatment regimens, with or without alpha/beta-defensins therapy. Serum concentrations of IgG, IgM, IgA and salivary sIgA were analyzed. Patients were divided into five groups based on treatment protocols.<b>Results & conclusion:</b> Treatment variations impacted serum immunoglobulin levels, notably in Group III, whose patients received radiation treatment and immunotherapy with higher alpha/beta-defensins doses. Significant IgG changes correlated with oral mucositis risk and outcomes. Further trials are necessary for validation and clinical application.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"869-878"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics.","authors":"Iftekhar Mahmood, Zhaoyang Li","doi":"10.1080/1750743X.2024.2382081","DOIUrl":"10.1080/1750743X.2024.2382081","url":null,"abstract":"<p><p>Immunoglobulin G (IgG) therapies have been used for decades as standard treatment for patients with primary antibody deficiencies. Monitoring the pharmacokinetics (PK) of IgG is a key component in guiding treatment regimens. Despite the wealth of clinical experience, substantial gaps exist in our understanding of the true nature of IgGs and their disposition in humans. Furthermore, intrinsic and extrinsic factors may alter the PK of IgG, necessitating an individualized approach for patients. A comprehensive literature review was performed in order to summarize the PK of IgGs, examine the mechanisms of IgG disposition (including catabolism), outline considerations for special patient populations and discuss knowledge gaps and future perspectives for improving our understanding of IgG PK in relation to the individualized treatment paradigm.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"16 13","pages":"879-894"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic CAR-T cells for cancer immunotherapy.","authors":"Xinfeng Chen, Yaoxin Gao, Yi Zhang","doi":"10.1080/1750743X.2024.2408048","DOIUrl":"10.1080/1750743X.2024.2408048","url":null,"abstract":"<p><p>Autologous chimeric antigen receptor (CAR)-modified T (CAR-T) cell therapy has displayed high efficacy in the treatment of hematological malignancies. Up to now, 11 autologous CAR-T cell products have been approved for the management of malignancies globally. However, the application of autologous CAR-T cell therapy has many individual limitations, long time-consuming, highly cost, and the risk of manufacturing failure. Indeed, some patients would not benefit from autologous CAR-T cell products because of rapid disease progression. Allogeneic CAR-T cells especially universal CAR-T (U-CAR-T) cell therapy are superior to these challenges of autologous CAR-T cells. In this review, we describe basic study and clinical trials of U-CAR-T cell therapeutic methods for malignancies. In addition, we summarize the problems encountered and potential solutions.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1079-1090"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}